HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Carcinomatosis — Clinical Guidelines

Overview

Peritoneal carcinomatosis involves the spread of cancer within the peritoneal cavity, often leading to complex symptom management and palliative care needs. 1

Diagnosis

Clinical presentation includes abdominal pain, ascites, and gastrointestinal symptoms. 1 3

Imaging studies such as CT and MRI are crucial for assessing extent and spread. 1

Cytology analysis of peritoneal fluid can confirm malignancy but has limitations in sensitivity. 2

Management

First-line: Cytoreductive surgery (CRS) combined with intraperitoneal hyperthermic chemotherapy (IPHC) for selected patients with colorectal cancer PC, aiming for optimal cytoreduction 4.

Palliative care: Focus on symptom management, including ostomy care and pain control, often requiring multidisciplinary support 1.

Intraventricular chemotherapy: Considered for leptomeningeal carcinomatosis, particularly from non-small-cell lung cancer, though efficacy is limited 2.

Special Populations

Caregiver preparedness: High caregiver burden noted; formal training in symptom management is often lacking 1.

Elderly: Older patients may have poorer outcomes due to comorbidities and performance status 2.

Key Recommendations

Implement cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for eligible patients with peritoneal carcinomatosis, particularly colorectal cancer, to improve survival (Evidence: Strong 4).

Provide comprehensive training and support for caregivers managing complex symptoms at home (Evidence: Moderate 1).

Consider intraventricular chemotherapy for symptomatic leptomeningeal carcinomatosis, though with realistic expectations of limited efficacy (Evidence: Weak 2).

References

1 Pozzar RA, Wall JA, Tavormina A, Thompson E, Enzinger AC, Matulonis UA et al.. Experiences of patients with peritoneal carcinomatosis-related complex care needs and their caregivers. Gynecologic oncology 2024. link 2 Gwak HS, Joo J, Kim S, Yoo H, Shin SH, Han JY et al.. Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2013. link 3 Suzuki M, Narita M, Hasegawa M, Furuta S, Kawamata T, Ashikawa M et al.. Sensation of abdominal pain induced by peritoneal carcinomatosis is accompanied by changes in the expression of substance P and μ-opioid receptors in the spinal cord of mice. Anesthesiology 2012. link 4 Al-Shammaa HA, Li Y, Yonemura Y. Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. World journal of gastroenterology 2008. link

Carcinomatosis